30 results about "Pharmaceutical Adjuvants" patented technology

The invention relates to the technical field of medical supplies, in particular to a wound repair medical dressing containing glycosylglycerol, and a dressing solution for the wound repair medical dressing comprises the following raw materials: carbomer 940, medical glycerol, glycosylglycerol, sodium hyaluronate, purified water, 1, 2-hexanediol, 1, 3-butanediol and a pharmaceutical adjuvant sodium hydroxide. The dressing is extruded to a skin wound surface or an affected part to form a thin film structure, a physical barrier is formed, the wound surface or the affected part is isolated from the external environment, the wound surface is protected from being polluted by the external environment, a microenvironment is provided for non-chronic wound surface healing, a protective layer is formed on the surface of the wound surface, the physical barrier effect is achieved, and the wound surface is protected. The dressing is used for nursing superficial wounds such as small wounds, scratches and incisions and surrounding skin; the contained components do not have pharmacological effects and cannot be absorbed by a human body.

The utility model discloses an anti-accumulation feeding device for pharmaceutic adjuvant production, which comprises an outer charging barrel, an inner charging barrel is arranged in the outer charging barrel, and a filter screen plate is arranged at the bottom end of the inner charging barrel. Through the arrangement of an anti-accumulation assembly, a first motor drives a first rotating rod to rotate, and then a cam is driven to rotate; the outer side of the cam abuts against the outer side of the connecting ring, along with rotation of the cam and cooperation of elastic potential energy of the reset spring, the connecting ring and the inner material barrel connected with the connecting ring can be continuously pushed to do up-down reciprocating motion, and the reciprocating motion can effectively prevent the pharmaceutic adjuvants from being accumulated on the filter screen plate; the medical auxiliary materials can be smoothly filtered through the filter screen plate, so that the feeding efficiency is improved, meanwhile, automatic control is achieved, the filter screen plate does not need to be manually and frequently cleaned, the labor intensity of operators is relieved, the automation degree of a production line is improved, and the whole production process is more efficient and stable.

The invention relates to the technical field of biological medicine, in particular to centipeda minima extracellular vesicle nose drops and a preparation method and application thereof.The centipeda minima extracellular vesicle nose drops comprise active ingredients, plant extracellular vesicles (Cm-EVs) derived from centipeda minima, the concentration of the plant extracellular vesicles (Cm-EVs) is 1 * 10 < 10 >-5 * 10 < 11 > particles / ml; the key active substances are as follows: the content of the Cm-EVs naturally encapsulated sesquiterpene lactone compound centipederin is more than or equal to 50 micrograms per milliliter (detected by HPLC-MS); the pharmaceutical auxiliary materials comprise 0.05 to 0.2 percent (w / v) of sodium hyaluronate, 0.8 to 1.0 percent (w / v) of NaCl and 0.005 to 0.02 percent (v / v) of polysorbate 80; the method has the beneficial effects that the targeted enrichment capability is realized: mucous membrane adhesion is enhanced through surface pectin protein, and the nasal cavity residence time is prolonged to 6 hours (the free medicine is less than 1 hour); the nano-scale particle size (80-200nm) can efficiently penetrate through the mucous layer, and the nasal mucosa drug concentration reaches 20 times of the plasma concentration (rat pharmacokinetic data); the long-acting slow-release property is as follows: the active ingredients are protected by the lipid bilayer, the cumulative release rate of the centipederin within 72 hours reaches 82%, and the free medicine can be completely released within 24 hours.

The present invention belongs to the field of pharmaceutical technology and, specifically, relates to a pharmaceutical composition and its use. The pharmaceutical composition comprises 1 wt% to 70 wt% of a compound of Formula (I) or a pharmaceutically acceptable salt, crystalline form, or isomer thereof and at least one pharmaceutical adjuvant. Through research, the present invention has developed a pharmaceutical composition that can be manufactured into a final formulation such as tablets, capsules, granules, etc. When the pharmaceutical composition is manufactured into a tablet, it has good compressibility compared to other pharmaceutical combination methods, while having good solubility and good particle fluidity;

The invention relates to the technical field of prevention and treatment of complications after organ transplantation, and discloses a preparation for preventing and treating diabetes mellitus after organ transplantation based on a Treg cell metabolic regulation function and application, the preparation takes repair or enhancement of the Treg cell metabolic regulation function as a core action mechanism, and comprises at least one active component, according to the PTDM prevention and treatment preparation based on the Treg cell metabolic regulation function and the application, the preparation contains IL-2 / anti-CD3 / CD28 beads, FKBP12siRNA, a PPAR-gamma agonist, SOCS-3siRNA and other active ingredients, and the active ingredients are matched with pharmaceutical auxiliary materials to be prepared into an injection or a freeze-dried powder injection; the preparation is suitable for PTDM high-risk recipients using CNI after kidney / heart transplantation, has a single drug and combination scheme, can also amplify Treg cells in vitro for transfusion to assist intervention, can realize'immune tolerance-metabolic regulation 'double-effect synergy, accurately target PTDM key pathways, adapt to multiple transplantation types, and can be combined with CPB for blood perfusion to synergistically reduce PTDM and AKI risks, reduce non-target injury and improve the curative effect of the PTDM. The life quality of a recipient is improved, the medical burden is reduced, and the blank of PTDM immunotherapy is filled.

The present application relates to the field of microbial technology, in particular to a kind of complex microbial agent comprising Bacillus velezensis TA-5 strain and application thereof.The microbial agent of the present application comprises (1) live bacteria, freeze-dried bacteria, inactivated bacteria or strain culture of Bacillus velezensis TA-5 strain; (2) Bacillus subtilis and / or chitosan oligosaccharide, and / or pesticide acceptable pharmaceutical adjuvant;Wherein, the preservation number of the Bacillus velezensis TA-5 strain in China General Microbiological Center for Preservation and Management of Microbial Strains is CGMCC NO.33034.It is used on fruit and vegetable with disease and can have excellent control effect, especially in field test, excellent effect is obtained;At the same time, the use amount of chemical preparation is reduced, and it is safe and environment-friendly, which provides a new idea for agricultural prevention and control.

The invention belongs to the technical field of pharmaceutical adjuvant synthesis, and particularly relates to a novel aqueous dispersion as well as a preparation method and application thereof. The novel aqueous dispersion comprises a film-forming agent, a plasticizer, an emulsifier and a solvent, wherein the film-forming agent is methyl cellulose and ethyl cellulose, the plasticizer is dibutyl sebacate, the emulsifier is ammonium oleate, and the solvent is purified water; the proportions of the methyl cellulose, the ethyl cellulose, the dibutyl sebacate, the ammonium oleate and the purified water in the total mass of the aqueous dispersion are 0.9 to 1.7 percent, 19 percent, 2.3 to 3.4 percent, 1.9 to 2.3 percent and 74 to 76 percent respectively; the solid content of the aqueous dispersion is 23%-26%, the viscosity of a 24.5% aqueous solution is 400-1500 mPa.s, and the pH value is 9.5-11.5. The novel aqueous dispersion disclosed by the invention has the characteristics of excellent performance, good film-forming property, high stability and the like, is convenient to apply, does not need additional auxiliary materials and heat treatment for coating, and more importantly, has an excellent slow-release effect, can realize long-time uniform release of medicines, and meets the slow-release coating requirements of oral medicines.

The present application aims to provide a sucrose hydroxyl ferric oxide tablet composition and a preparation method thereof. The present application belongs to the technical field of pharmaceutical preparations, and particularly relates to a sucrose hydroxyl ferric oxide tablet composition and a preparation method thereof. The sucrose hydroxyl ferric oxide is a particle with a certain particle size distribution, and the pharmaceutical composition is prepared by adding pharmaceutically acceptable pharmaceutical adjuvants, the preparation method is simple, the product has small friability, is easy to package, and is more conducive to commercial production.

The present application provides a kind of pharmaceutical composition, the composition comprises therapeutically effective amount of bucumidol, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutical adjuvant, the specific antioxidant is selected from one or more of the following: lipid-soluble vitamin C derivative, or phenolic antioxidant.In addition, a method for improving the stability of bucumidol pharmaceutical composition is also disclosed.The technical scheme of the present application effectively solves the problem of the generation and growth of N-nitroso-bumetanide and other related substances in the production and storage of bucumidol solid preparation, significantly improves the stability of the drug and the safety of drug use.

The present application relates to a kind of amoxicillin gastric retention sustained-release preparation, which contains amoxicillin, sustained-release material, swelling agent and other pharmaceutical adjuvant, preferably also contains stabilizer or ion regulator.The combination of the above-mentioned adjuvant can be retained in the stomach for up to 24 hours, the complete release time is 10-24h, which can significantly prolong the retention time of amoxicillin in the stomach, has the advantages of fast floating, high effective concentration of drug in the stomach, long stable concentration time, and is beneficial to reduce the frequency of drug administration of patients;Further preferably, it is made into a double-layer tablet containing immediate-release layer, which can quickly reach effective concentration and also can be released slowly and continuously, maintaining effective concentration for a long time;When combined with proton pump inhibitors such as vonolabian, etc., combination kit or compound, only 1-2 times per day is needed, which can further improve the therapeutic effect and patient compliance.

The invention relates to an osmotic pump tablet as well as a preparation method and application thereof. The osmotic pump tablet comprises a tablet core and a coating film wrapping the tablet core, the coating film is provided with drug release holes, the tablet core comprises a drug-containing layer, the drug-containing layer comprises active pharmaceutical ingredients, a hydrophilic polymer and a surfactant, the hydrophilic polymer comprises hydroxypropyl cellulose, and the surfactant comprises poloxamer; or the drug-containing layer comprises a drug active ingredient and a hydrophilic polymer, but does not contain a surfactant; the hydrophilic polymer is prepared from povidone K29 / 32; or the osmotic pump tablet contains the drug-containing quick-release outer coating, the drug-containing quick-release outer coating contains the active pharmaceutical ingredient and the pharmaceutic adjuvant, and the pharmaceutic adjuvant is an adhesive. The invention further provides a preparation method and application of the compound. The osmotic pump tablet disclosed by the invention is high in drug loading capacity and can well play a treatment effect.

The utility model discloses a batching device for medicinal auxiliary material production, which comprises a bracket, a crushing mesh enclosure is fixedly mounted at the inner top of a mixing tank, a compression roller is movably mounted on a rotating rod, and a conical auger is fixedly connected to the bottom of a mixing rod; through the design of structures such as a driving motor, a stirring rod, a crushing mesh enclosure, a compression roller and a conical auger, and through the cooperation of the driving motor, the stirring rod and the compression roller, solid raw materials falling into the crushing mesh enclosure can be extruded and crushed, and the solid raw materials and liquid raw materials can be stirred and mixed when the stirring rod rotates; meanwhile, solid and liquid can be stirred and turned over through the conical packing auger, so that the solid and liquid located at the bottom in the mixing tank can be turned over upwards, the solution can be fully mixed, the mixing efficiency is improved, the solid raw material extrusion and crushing and solid and liquid stirring and turning functions can be provided at the same time, the use cost of equipment can be reduced, and the equipment is suitable for popularization and application. And the practicability of the equipment is improved.

The utility model discloses a medicine assistant mixing device, which relates to the technical field of medicine assistant mixing and comprises a mixing cylinder, a plurality of input seats used for being communicated with medicine assistant input equipment are arranged at the upper end of the mixing cylinder, and a plurality of output seats used for outputting mixed medicine assistants are arranged at the lower end of the mixing cylinder. A rotating motor is arranged at the upper end of the mixing barrel, the fixed end of the rotating motor is fixedly connected with the mixing barrel, the output end of the rotating motor is fixedly connected with a stirring rod in the mixing barrel, and a cleaning mechanism used for cleaning the surface of the stirring rod is slidably connected to the stirring rod. A linkage assembly for scraping off the medicine auxiliaries on the inner wall of the mixing barrel in the stirring process of the stirring rod is arranged in the mixing barrel, a second sliding block is driven by a scraping block to slide in a sliding groove, the scraping block is driven by displacement of the second sliding block in the vertical direction to move in the vertical direction, the medicine auxiliaries with high viscosity on the inner wall of the mixing barrel are scraped off, and the medicine auxiliaries with high viscosity on the inner wall of the mixing barrel are scraped off. The medicine auxiliary agent is fully stirred, and the mixing efficiency of the medicine auxiliary agent is enhanced.

This invention concerns immunogenic B cell epitopes of the RPO30 protein of the Lumpy Skin Disease virus isolate from East Java as vaccine candidates in the field of animal health. This invention relates to the identification, characterization, and utilization of immunogenic B cell epitopes derived from the RPO30 protein of the Lumpy Skin Disease virus isolate from East Java. The identified B cell epitopes were selected from the group consisting of SL, D, TSSYESTSSQ, and QGMGGYT, which have the ability to induce specific humoral immune responses against the Lumpy Skin Disease virus. These B cell epitopes can be chemically synthesized or recombinantly expressed and formulated with a veterinary acceptable carrier or pharmaceutical adjuvant to produce an epitope-based vaccine candidate. This invention provides an alternative vaccine candidate that is safer than live attenuated vaccines, has the potential to reduce post-vaccination side effects, and is more specific to local Indonesian isolates.This invention is expected to be used for the prevention of Lumpy Skin Disease in cattle and buffalo.

The application discloses a kind of self-assembled nano-preparations based on hyaluronic acid-fatty acid coupling prodrug, the self-assembled nano-preparations use hyaluronic acid-fatty acid coupling prodrug as active ingredient, the hyaluronic acid-fatty acid coupling prodrug has structure shown in formula I, wherein, R is saturated or unsaturated fatty acyl;N=1~900, m=0~899.The application also discloses the preparation method of the above-mentioned self-assembled nano-preparations, and the application of the above-mentioned self-assembled nano-preparations in preparing anti-colitis drugs.The application avoids using pharmaceutical adjuvant, can avoid the allergic reaction and toxicity caused by adjuvant, has good biocompatibility and can be biodegraded, has good clinical conversion prospect.And it can realize intestinal inflammatory site and M1 macrophage target enrichment, eliminate excess ROS while inhibiting inflammatory response, has better anti-intestinal inflammation efficacy compared with clinical 5-amino salicylic acid, dexamethasone.

This invention relates to the field of pharmaceutical adjuvant technology, and discloses a composite nanoparticle formulation with enhanced microwave ablation effect on liver tumors, its preparation method, and its application, comprising the following steps: Step S1, reacting silica nanospheres, ammonia, and zirconium propofol (IV) in a mixed solvent composed of anhydrous ethanol and acetonitrile to obtain ZrO2@SiO2 nanospheres; Step S2, using NaOH solution to etch and remove the SiO2 template inside the ZrO2@SiO2 nanospheres to obtain hollow ZrO2 nanospheres; Step S3, loading copper nitrate into the hollow ZrO2 nanospheres to obtain a ZrO2@Cu(NO3)2 intermediate; Step S4, dispersing the intermediate with PVP and H2BDC in DMF, and reacting under sealed and constant temperature to obtain ZrO2@CuO / Cu-MOF composite nanoparticles. The composite nanoparticles obtained by this scheme can be used as microwave ablation enhancers. The mesoporous structure of ZrO2 and the microwave absorption characteristics of Cu-based components work synergistically to effectively enhance the microwave ablation effect on tumors. At the same time, Cu-MOF can load drugs to achieve synergistic treatment of "ablation + chemotherapy".

The invention discloses a tumor vaccine adjuvant based on interleukin-12 (IL-12). Active components of the GM-CSF / IL-12 / IFN-gamma fusion protein comprise GM-CSF, IL-12 and IFN-gamma according to a mass ratio of 1: (0.1 to 10): (0.01 to 5), preferably 1: (0.5 to 2): (0.1 to 1). The purity of the active component is not lower than 95.0%, and the endotoxin content is lower than 10 EU / mg. The adjuvant contains pharmaceutic adjuvants and can be prepared into liquid or freeze-dried powder. The invention further relates to a composition containing the adjuvant and tumor antigens (such as neoantigen, mRNA and the like), and the mass ratio of the active ingredients of the antigens to the adjuvant is (5-500): 1. The bonding approach encompasses physical mixing, co-encapsulation of nanoparticles, or chemical coupling. The traditional Chinese medicine composition can obviously enhance immune response and is suitable for preventing and treating various tumors such as melanoma and lung cancer.

The invention provides an application of a coumarin compound in preparation of a blood coagulation promoting drug, the drug is used for promoting the activity of a blood coagulation factor XI, and the coumarin compound is selected from isopsoralen, isobergapten, psoralen, bergamot phenol, xanthotoxol, 8-hydroxybergapten, isoenopileol, 8-(6-hydroperoxy-3, 7-dimethyl-2, 4, 6-triazole-3, 7-dimethyl-2, 4, 6-triazole-3, 7-triazole-3, 7-triazole-3, 7-triazole-3, 7-triazole-3, 7-triazole-3, 7-triazole-3, 7-triazole-3, 7- the active ingredient is any one selected from the group consisting of 2-(2, 6, 7-octadienyloxy) psoralen, fingered citron lactone and 8-geranyl oxy-psoralen. The invention also provides application of the coumarin compound or the pharmaceutically acceptable salt thereof in preparation of a blood coagulation factor XI activator, and further provides a blood coagulation promoting drug composition. The pharmaceutical composition comprises any one or a combination of the coumarin compound or the pharmaceutically acceptable salt thereof, and pharmaceutical adjuvants acceptable for a coagulant drug.

The invention discloses a method for accurately predicting the interaction between pharmaceutic adjuvants and proteins based on a cross attention mechanism and a deep transfer learning strategy. The method comprises the following steps: firstly, collecting large-scale drug-like molecule-protein activity data and pharmaceutic adjuvant-protein interaction data; secondly, constructing an interaction prediction model framework based on a cross attention mechanism; then, inputting the drug-like molecular structure and the protein sequence into the prediction model, and training to obtain a pre-trained model PreDIG; then, the pharmaceutic adjuvant structure and the protein sequence serve as input, a deep transfer learning strategy is used, a PreDIG model is subjected to fine tuning training, and a BioDIG model is obtained; and finally, inputting the to-be-detected pharmaceutic adjuvant structure and the protein sequence into BioDIG to obtain the to-be-detected pharmaceutic adjuvant-protein interaction prediction probability, and judging whether the pharmaceutic adjuvant is combined with the protein or not according to the pharmaceutic adjuvant-protein interaction prediction probability.

The invention discloses alpha-glucan extracted from bamboo bird's nests as well as a preparation method and application of the alpha-glucan. The molecular weight of the glucan is 11.27 kDa, and a main chain of the glucan is formed by alternately connecting-> 4)-alpha-D-Glcp-(1-> and-> 3)-alpha-D-Glcp-(1->. The preparation method comprises the steps of hot water extraction, ethanol precipitation, QFF anion exchange column and Sephacryl S-200 gel column purification and the like. Experiments show that the polysaccharide can effectively regulate intestinal flora, significantly improve the levels of acetic acid, propionic acid and other short-chain fatty acids in intestinal tracts, and have a good relieving effect on intestinal injury caused by antibiotic or tumor treatment. Therefore, the glucan disclosed by the invention can be used as an excellent prebiotic and is used for developing functional foods or medicine adjuvants for regulating intestinal health.

The present invention relates to a new use of γ-glutamylcysteine (GGC), specifically to the application of GGC in the preparation of drugs for treating rheumatoid arthritis (RA) and a pharmaceutical composition for treating rheumatoid arthritis. The pharmaceutical composition for treating rheumatoid arthritis can be made into tablets, capsules, granules, drops, granules, ointments or injections by adding general pharmaceutical adjuvants to GGC with a purity of more than 95% (mass percentage). The results of pharmacological experiments show that GGC can significantly improve the joint swelling of rheumatoid arthritis, reduce the arthritis index, reverse the pathological changes of arthritis, and has no serious disadvantages of commonly used clinical drugs, indicating that GGC has a strong effect against rheumatoid arthritis. Therefore, GGC can be used to prepare drugs for treating rheumatoid arthritis. The present invention provides a new drug source for the treatment of rheumatoid arthritis.

The present invention discloses the use of the small molecule compound GI-Y2 in the preparation of a drug for inhibiting pyroptotic inflammation to prevent or treat atherosclerosis. The small molecule compound uses GI-Y2 as an active ingredient and can be prepared by adding conventional pharmaceutical adjuvants. The pharmaceutical active ingredient GI-Y2 in the present invention is simple to synthesize and has the effect of specifically targeting gasdermin D (GSDMD) to inhibit pyroptosis, thereby exhibiting excellent anti-inflammatory activity. The role of GSDMD-mediated macrophage pyroptosis in promoting atherosclerosis is clear, and the effect of GI-Y2 in targeting and inhibiting GSDMD is significant, which can effectively prevent or treat atherosclerosis. The small molecule compound GI-Y2 provides a new treatment strategy for atherosclerosis and has broad application prospects.

The invention discloses a self-assembled nano preparation based on a hyaluronic acid-fatty acid coupled prodrug, the self-assembled nano preparation uses the hyaluronic acid-fatty acid coupled prodrug as an active ingredient, the hyaluronic acid-fatty acid coupled prodrug has a structure as shown in a formula I, R is saturated or unsaturated fatty acyl; n is equal to 1-900, and m is equal to 0-899. The invention also discloses a preparation method of the self-assembled nano preparation, and an application of the self-assembled nano preparation in preparation of anti-colitis drugs. According to the invention, the use of pharmaceutical excipients is avoided, anaphylactic reaction and toxicity caused by the excipients can be avoided, the biocompatibility is good, the material can be biodegraded, and the material has a good clinical transformation prospect. And the dexamethasone can realize targeted enrichment at intestinal inflammation parts and in M1 macrophages, eliminates excessive ROS (reactive oxygen species) and inhibits inflammatory reaction at the same time, and compared with clinical 5-aminosalicylic acid, the dexamethasone has a better anti-enteritis curative effect.

The invention provides a preparation method of a Yulan hypoglycemic capsule pharmaceutical composition. The preparation method comprises the following steps: crushing radix scutellariae, folium mori and other traditional Chinese medicinal materials into coarse powder, adding a betaine-malic acid aqueous solution, and carrying out ultrasonic extraction and filtration to obtain an extract A and medicine residues A; carrying out heating reflux extraction on the medicine residue A by using an ethanol solution, and sieving to obtain an extract B; combining the extract A and the extract B, adding ethanol, refrigerating, and finally concentrating into thick paste; various pharmaceutical auxiliary materials can be added into the obtained thick paste to prepare corresponding pharmaceutical preparations. The process can solve the problems of low baicalin content, more water-soluble impurities and the like in the traditional process, the product quality is stable, the indexes meet regulations, and the process is suitable for actual production.

The invention discloses a synthetic method of medicinal-grade calcium hydrophosphate dihydrate, and belongs to the field of pharmaceutical adjuvant synthesis. The preparation method comprises the following steps: firstly, adding calcite into dilute phosphoric acid to obtain mixed slurry; lime milk and sodium pyrophosphate are slowly added into the mixed slurry, nucleation is carried out under the assistance of ultrasonic waves, magnesium hydrogen phosphate is continuously added after the reaction is carried out to a certain degree, and calcium hydrogen phosphate dihydrate slurry is obtained through microwave heating treatment; and finally, carrying out centrifugal filtration, pneumatic drying and grading to obtain the medicinal-grade calcium hydrophosphate dihydrate. According to the technology, nucleation and growth of crystals are regulated and controlled through multi-means and multi-step neutralization reactions, and the finally prepared calcium hydrophosphate dihydrate is high in sphericity degree, uniform in size distribution, good in fluidity, high in main component content, low in impurity content and good in stability, meets the related standard of calcium hydrophosphate dihydrate in Chinese pharmacopoeia and has good application prospects. The method is suitable for preparing and forming high-quality solid preparations.

The invention relates to the technical field of analytical chemistry detection, in particular to a method for determining trace nitrite in pharmaceutic adjuvants. The method comprises the following steps: weighing a test sample, placing the test sample in a measuring flask, adding acetonitrile according to a ratio, and dispersing the sample by vortex oscillation; adding a pre-prepared nitrite reference stock solution, adding water, shaking, mixing and diluting, and shaking uniformly to obtain a standard test solution; preparing a standard-free test solution which does not contain the reference stock solution as a reference; taking supernate of the labeled test sample solution, enabling the supernate to sequentially pass through an activated silver column and an activated sodium column, filtering the supernate through a PES filter membrane, discarding initial filtrate, and collecting subsequent filtrate for later use; measuring the nitrite reference substance stock solution, diluting the nitrite reference substance stock solution with an acetonitrile-water mixed solvent, and preparing reference substance solutions with different concentrations for later use; a labeled test solution, a non-labeled test solution and reference solutions with different concentrations are respectively subjected to sample introduction detection under preset ion chromatography conditions, so that the content of trace nitrite in the pharmaceutic adjuvant can be accurately and quantitatively determined.

The invention discloses a high-stability cortex fraxini coumarin composition, the composition is composed of a solid preparation containing cortex fraxini coumarin and a liquid preparation containing borneol, a buffer solution and pharmaceutic adjuvants, and based on the research on the stability of cortex fraxini coumarin and the clinical application requirements of Qinican eye drops, the pharmaceutical adjuvants are prepared. A novel preparation scheme of a solid-liquid split preparation is provided for the application of the fraxinol coumarin to the fraxinol eye drops, the unstable state of long-term storage of the fraxinol coumarin in the eye drops can be avoided, the medicine stability is remarkably improved, the accuracy of the dosage of the fraxinol eye drops in the treatment process is improved, the curative effect of the medicine is guaranteed, and the medication safety is improved.

The invention discloses a method for separating and detecting cetirizine isomers in levocetirizine hydrochloride oral liquid, levocetirizine hydrochloride and dexcetirizine hydrochloride as well as dexcetirizine hydrochloride and pharmaceutical adjuvant peaks can be effectively separated by the separation and detection method, and dexcetirizine hydrochloride can be accurately and efficiently separated and detected by the method. The method can be used for quality control of dexcetirizine hydrochloride drug detection.

This invention concerns the RPO30 protein of an Indonesian isolate of Lumpy Skin Disease virus and its use in the development of an epitope-based vaccine in the field of animal health. This invention relates to the provision of the RPO30 protein or its immunogenic B cell epitope fragment derived from an Indonesian isolate of Lumpy Skin Disease virus as an active vaccine ingredient. The RPO30 protein or the immunogenic B cell epitope fragment is identified through genetic sequence analysis and immunogenicity prediction, then chemically synthesized or recombinantly expressed. The immunogenic B cell epitope fragment is then formulated with a veterinary acceptable carrier or pharmaceutical adjuvant to produce an epitope-based vaccine. This epitope-based vaccine is designed to induce a specific humoral immune response against Lumpy Skin Disease virus without the use of live virus.This invention provides an alternative for developing a safer vaccine, specific to local Indonesian isolates, and potentially reducing post-vaccination side effects. It is hoped that this invention can be used to prevent Lumpy Skin Disease in cattle and buffalo.

The invention relates to the technical field of medicinal auxiliary material disinfection, and discloses a disinfection device for medicinal auxiliary material production, the disinfection device comprises an equipment rack, support plates are fixedly mounted on the front and rear sides of the upper end surface of the equipment rack, a rotating column is rotatably mounted on the inner side wall of the support plate located on the front side, and a cleaning box is fixedly mounted on the side wall of the rotating column; a draining box is fixedly mounted on the left end face of the equipment frame, and the turnover mechanism is arranged in the middle of the front end face of the cleaning box; the stirring mechanism is arranged in the middle of the inner cavity of the cleaning box; the liquid injection mechanism is arranged in the middle of the rear end face of the cleaning box; and a draining mechanism. Through the arrangement of the stirring mechanism and the liquid injection mechanism, the pharmaceutical excipients in the cleaning box can be fully stirred, and meanwhile, through the arrangement of the turnover mechanism and the draining mechanism, the pharmaceutical excipients can be rapidly dried, so that the disinfection efficiency and quality of the whole device on the pharmaceutical excipients are improved.